SynSmart Rasayan Research Private Limited and Amporin Pharmaceuticals AG have partnered to create new medicines for serious and life-threatening diseases that damage the body over time.
As part of this partnership, SynSmart will develop a large number of new molecules at its research center in Mumbai. These molecules are designed to protect cell membranes, which are important for keeping cells healthy.
After testing these molecules, the companies may continue working together on further research and development. This could include improving the molecules and studying how they behave in the body, with the goal of selecting the best candidates for future medicines.
Commenting on this, Mr. Saurabh Kapure, CEO at SynSmart said, “This collaboration is a testimony of value that SynSmart can bring to the table for its partners. With lab operations running in multi-shift mode and lean team hierarchy, the speed and cost-savings help partners get more done for less.”
Also commenting on this, Dr. Kelvin Stott, Founder and CEO at Amporin said, “We are excited to form this collaboration with SynSmart as it will accelerate the cross-target screening, optimization and selection of disease-modifying treatments for multiple deadly degenerative diseases in parallel, while validating the scope and potential of our unique asset platform.”
About SynSmart
SynSmart is a specialized chemistry company that helps biotech and large pharmaceutical companies with research and development work. It provides services like custom synthesis and medicinal chemistry to more than 40 clients, working on different business models based on time or project needs.
The company has a team of over 125 chemists and works in areas such as small molecules and complex peptides. It also uses advanced techniques such as photochemistry and flow chemistry. With these capabilities, SynSmart is expanding its services and strengthening its position in new and growing areas of drug development across global markets.
About Amporin Pharmaceuticals
Amporin Pharmaceuticals AG is a growing Swiss biotech company developing a new type of small-molecule medicines. These medicines are designed to block and repair damage in cell membranes and mitochondrial membranes caused by misfolded proteins.
By repairing this damage, the goal is to help cells function normally again and possibly slow, stop, or even reverse many serious diseases. These include conditions like ALS, Alzheimer’s disease, Parkinson’s disease, Type 2 diabetes, as well as several rare diseases.
